ARK Investment Management Adds $9M in Recursion Pharmaceuticals, Inc. ($RXRX)
Key Points
- ARK Investment Management changed its Recursion Pharmaceuticals, Inc. ($RXRX) stake by 7.8% last quarter, boosting to 40,212,769 shares worth $126.67 million.
- $RXRX last traded around $3.15.
ARK Investment Management increased its position in Recursion Pharmaceuticals, Inc. ($RXRX) by 7.8% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 40,212,769 shares of Recursion Pharmaceuticals, Inc. after buying 2,895,913 shares during the quarter. ARK Investment Management's holdings in Recursion Pharmaceuticals, Inc. were worth $126.67 million as of its most recent filing.
Recursion Pharmaceuticals, Inc. ($RXRX) Stock
Recursion Pharmaceuticals, Inc. Earnings
Analysts Set New Price Targets
About Recursion Pharmaceuticals, Inc.
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology. Its preclinical stage product includes REC-7735 for the treatment of HR+ breast cancer; and REC-102 for the treatment of hypophosphatasia. The company has collaboration and agreement with Roche & Genentech; Sanofi; Bayer AG; Tempus; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.